AQR Capital Management
ACET icon

AQR Capital Management’s Adicet Bio ACET Stock Holding History

AQR Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,548
Closed -$165K – 2752
2024
Q2 		$165K Buy
8,548
+7,070
+478% +$189K ﹤0.01% 2449
2024
Q1 		$55.6K Buy
+1,478
New +$61.1K ﹤0.01% 2371
2023
Q4 		– Sell
-4,689
Closed -$103K – 2323
2023
Q3 		$103K Buy
+4,689
New +$166K ﹤0.01% 2229
2023
Q1 		– Sell
-996
Closed -$142K – 2155
2022
Q4 		$142K Buy
996
+214
+27% +$53.4K ﹤0.01% 2108
2022
Q3 		$178K Buy
+782
New +$198K ﹤0.01% 2056

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

AQR Capital Management's ACET Position: Q3 2024 in Review

AQR Capital Management sold out of Adicet Bio (ACET) in Q3 2024, closing a stake of 8,548 shares — an estimated $165K sold.

AQR Capital Management first reported a position in ACET in Q3 2022 and held it in 5 quarters. The position peaked at $178K in Q3 2022. 64 funds tracked by Wall St. Rank hold ACET as of Q3 2024.

  • AQR Capital Management reported no remaining Adicet Bio position as of Q3 2024 after selling out during the quarter.
  • AQR Capital Management sold 8,548 Adicet Bio shares in Q3 2024, an estimated $165K.
  • AQR Capital Management first reported a position in Adicet Bio in Q3 2022 and held it in 5 quarters.
  • AQR Capital Management's Adicet Bio position peaked at $178K in Q3 2022.
  • 64 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2024.

Based on AQR Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.